Search filters

Filters
Clear All

Phase

  • 10
  • 16
  • 17
  • 11
  • 21
  • 79
  • 37
  • 3
  • 2
  • 74
  • 77
  • 2

Found 79 Chemotherapy trials

A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

18 years - 65 years
All genders
Phase 1
Interventional
This research study is for people who have been waiting for a kidney transplant for at least one year, and who have a cPRA of 99.5% or higher. Having a cPRA of 99.5% or higher means that your immune system would reject 99.5% of kidneys available for transplant. The study …
 Evaluating in vivo PARP-1 expression with 18F-FluorThanatrace positron emission tomography (PET/CT) in Pancreatic Cancer
99 years or below
All genders
Phase 1
This is a pilot study in patients with histologically proven pancreatic adenocarcinoma who have demonstrated at least stable disease following at least 16 weeks of treatment with platinum-based chemotherapy and are recommended for treatment with a PARP inhibitor with or without additional agents, either as part of their clinical care …
 Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer
99 years or below
All genders
Phase 1
Surgery is the best treatment for patients with Stage I or II lung cancer; however, nearly 60% of patients have recurrence. Additional immunotherapeutic agents given before surgery may be greatly reduce recurrence. This is a Standard Phase I, 3+3 dose escalation trial designed to evaluate the safety and toxicity of …
 Detection of cell-free circulating tumor DNA in patients with glioblastma undergoing treatment with first-line chemoradiotherapy
99 years or below
All genders
Glioblastoma (GBM) is the most common primary brain tumor in adults and is uniformly fatal. During standard adjuvant treatment for GBM following initial surgical resection of the tumor, patients are treated with a combination of radiation and chemotherapy. During and after this adjuvant treatment, patients are monitored for disease progression …
100 years or below
Male
-For US: Aged 10 to 25 years on the day of inclusion ("10-25 years" means from the day of the 10th birthday to the day before the 26th birthday) For EU: Aged 42 to 89 days or 12 to 18 months or 10 to 50 years on the day of …
 BEAT-MS Multiple Sclerosis Trial
18 years - 55 years
All genders
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.All participants will be followed …
 Gene Transfer for Patients With Sickle Cell Disease Using a Gamma Globin Lentivirus Vector
18 years - 99 years
All genders
Phase 1
This Phase 1/2 study will use a novel therapy, ARU-1801, for Sickle Cell Disease, using gene transfer of recombinant -globin lentivirus (LV) vector. The purpose of this study, which involves research, is to determine whether an experimental procedure called “gene transfer” is safe and effective. If you are interested in …
 Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
18 years - 99 years
Female
Observational
This is a prospective natural history study of CIPN in approximately 200 participants receiving taxanes (paclitaxel, docetaxel) for breast cancer or vincristine for lymphoma. Participants will be enrolled over approximately 1-year.The purpose of this present study is to prospectively collect clinical and biomarker data from patients receiving neurotoxic chemotherapy who …
99 years or below
All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
99 years or below
All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.